Advanced in Pol 3-Related Leukodystrophy

Dr. Stephen S. Flitman

Neurology
2601 N 3rd St, Suite 125, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients

Advanced in Pol 3-Related Leukodystrophy
2601 N 3rd St, Suite 125, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Flitman is a Neurologist in Phoenix, Arizona. Dr. Flitman is rated as an Advanced provider by MediFind in the treatment of Pol 3-Related Leukodystrophy. His top areas of expertise are Migraine with Brainstem Aura, Migraine, Memory Loss, and Drug Induced Dyskinesia. Dr. Flitman is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in AZ
Hospital Affiliations
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

2601 N 3rd St, Suite 125, Phoenix, AZ 85004
Call: 602-265-6500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Enrollment Status: Recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drug: Galcanezumab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drug: LY3451838
Study Phase: Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

1 Total Publications

Treatment of migraine with occipital nerve blocks using only corticosteroids.
Treatment of migraine with occipital nerve blocks using only corticosteroids.
Journal: Headache
Published: January 05, 2011
Similar Doctors
Experienced in Pol 3-Related Leukodystrophy
Dr. Arun A. Kumar
Neurology
Experienced in Pol 3-Related Leukodystrophy
Dr. Arun A. Kumar
Neurology

Valley Institute Of Neurology PLLC

6750 E Baywood Ave, Suite 502, 
Mesa, AZ 
 (22.6 miles away)
480-854-7100
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Arun Kumar is a Neurologist in Mesa, Arizona. Dr. Kumar is rated as a Distinguished provider by MediFind in the treatment of Pol 3-Related Leukodystrophy. His top areas of expertise are Spinocerebellar Ataxia Type 23, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 14, and Spinocerebellar Ataxia Type 12. Dr. Kumar is currently accepting new patients.

Experienced in Pol 3-Related Leukodystrophy
Dr. Guillermo D. Moguel-Cobos
Neurology
Experienced in Pol 3-Related Leukodystrophy
Dr. Guillermo D. Moguel-Cobos
Neurology

Sjhmc Physician Services

500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
 (0.7 miles away)
602-406-6017
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Guillermo Moguel-Cobos is a Neurologist in Phoenix, Arizona. Dr. Moguel-Cobos is rated as a Distinguished provider by MediFind in the treatment of Pol 3-Related Leukodystrophy. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Movement Disorders, Focal Dystonia, and Deep Brain Stimulation. Dr. Moguel-Cobos is currently accepting new patients.

VIEW MORE POL 3-RELATED LEUKODYSTROPHY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flitman's expertise for a condition
ConditionClose
    • Distinguished
    • Memory Loss
      Dr. Flitman is
      Distinguished
      . Learn about Memory Loss.
      See more Memory Loss experts
    • Migraine
      Dr. Flitman is
      Distinguished
      . Learn about Migraine.
      See more Migraine experts
    • Migraine with Brainstem Aura
      Dr. Flitman is
      Distinguished
      . Learn about Migraine with Brainstem Aura.
      See more Migraine with Brainstem Aura experts
    • Advanced
    • Acute Cerebellar Ataxia
      Dr. Flitman is
      Advanced
      . Learn about Acute Cerebellar Ataxia.
      See more Acute Cerebellar Ataxia experts
    • Alpers-Huttenlocher Syndrome
      Dr. Flitman is
      Advanced
      . Learn about Alpers-Huttenlocher Syndrome.
      See more Alpers-Huttenlocher Syndrome experts
    • Arachnoid Cysts
      Dr. Flitman is
      Advanced
      . Learn about Arachnoid Cysts.
      See more Arachnoid Cysts experts
    • Autosomal Dominant Partial Epilepsy with Auditory Features
      Dr. Flitman is
      Advanced
      . Learn about Autosomal Dominant Partial Epilepsy with Auditory Features.
      See more Autosomal Dominant Partial Epilepsy with Auditory Features experts
    • Behr Syndrome
      Dr. Flitman is
      Advanced
      . Learn about Behr Syndrome.
      See more Behr Syndrome experts
    • Brain Aneurysm
      Dr. Flitman is
      Advanced
      . Learn about Brain Aneurysm.
      See more Brain Aneurysm experts
    View All 52 Advanced Conditions
    • Experienced
    • Alternating Hemiplegia of Childhood
      Dr. Flitman is
      Experienced
      . Learn about Alternating Hemiplegia of Childhood.
      See more Alternating Hemiplegia of Childhood experts
    • Alzheimer's Disease
      Dr. Flitman is
      Experienced
      . Learn about Alzheimer's Disease.
      See more Alzheimer's Disease experts
    • Andermann Syndrome
      Dr. Flitman is
      Experienced
      . Learn about Andermann Syndrome.
      See more Andermann Syndrome experts
    • Apraxia
      Dr. Flitman is
      Experienced
      . Learn about Apraxia.
      See more Apraxia experts
    • Arachnoiditis
      Dr. Flitman is
      Experienced
      . Learn about Arachnoiditis.
      See more Arachnoiditis experts
    • Asperger's Syndrome
      Dr. Flitman is
      Experienced
      . Learn about Asperger's Syndrome.
      See more Asperger's Syndrome experts
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved